CROI 2018 (Retrovirus)

Ibalizumab phase 3 results and susceptibility to drug-resistant HIV

Statin use might reduce risk of cancer in HIV positive people

Featured 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)

Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques

No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification

Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment

Twice-daily dolutegravir is effective and tolerable with rifampicin 

Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin

Bictegravir at CROI 2018: switching studies and drug resistance analyses

PrEP at CROI 2018 (part 1): Access in Australia and the US

PrEP at CROI 2018 (part 2): Animal studies for future drugs

BHIVA best of CROI feedback workshops

CROI 2018 – highlights from the preliminary programme